CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Progesterone 100 MGWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug331 Best Available Therapy Wiki 1.00
drug1863 Plasma Wiki 0.58

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men

The purpose of this study is to assess safety and efficacy of progesterone for treatment of COVID-19 in hospitalized men.

NCT04365127 COVID-19 Sars-CoV2 Drug: Progesterone 100 MG

Primary Outcomes

Description: Change in clinical status of subjects at Day 15 based on the following 7-point ordinal scale Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen Not hospitalized, limitation on activities Not hospitalized, no limitations on activities

Measure: Change in clinical status of subjects at Day 15 based on the following 7-point ordinal scale

Time: 15 days

Secondary Outcomes

Description: Change in clinical status of subjects daily while hospitalized and at Day 29 based on the following 7-point ordinal scale Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen Not hospitalized, limitation on activities Not hospitalized, no limitations on activities

Measure: Change in clinical status of subjects assessed daily while hospitalized and on Day 29

Time: 29 days

Description: The length of time that the subjects require supplemental oxygen. The length of time that the subjects require mechanical ventilation (if applicable). The length of time that the subjects remain in the hospital.

Measure: Duration of supplemental oxygen, mechanical ventilation (if applicable), and hospitalization

Time: 29 days


No related HPO nodes (Using clinical trials)